CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2020 Earnings Conference Call - Final Transcript

Aug 06, 2020 • 05:30 pm ET

Previous

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2020 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Q & A
Operator
Operator

Thank you. [Operator Instructions] Our first question comes from Peter Lawson of Barclays. Your line is open.

Analyst
Waleed

Hey guys, this is Waleed on for Peter, and thanks for taking the question. Just maybe initially on the expansion study for CX-2009. Just wondering, if you could give us a little bit more color and details on the revised patient enrollment criteria for the study. And also based on your discussions with the FDA, what is the bar you need to hit and what would be considered positive results in both HER2-negative breast cancer, as well as, triple negative. Thank you.

Executive
Sean A. McCarthy

Yes. Great, thanks for the questions. So, regarding patient enrollment, the kinds of things that we're looking at obviously are given that the Phase 1 data for 2009 was generated in a very heavily pre-treated patient population with a median number of prior treatments of seven or eight depending upon whether it's TNBC or hormone receptor positive. Obviously, we're looking to enroll a substantially less heavily pre-treated patient population in the study, so we've been fine-tuning that in the recent months. Also, given the evolution of the landscape giving a little bit more thought to prior treatment regimens that are allowed in this study in regards to the patient population. So, those are the kinds of things that we're doing in this intervening period.

Regarding the bar for activity, still I want to emphasize this is still a relatively early expiration of 2009 in breast cancer. It is a rapidly evolving field, both in hormone receptor positive and triple-negative. We haven't yet had formal discussions with FDA on these types of matters. But the -- in triple-negative, of course, we're very well aware of the approval now for the -- of sacituzumab and the activity that we've seen with that molecule in hormone receptor positive where sacituzumab is also active. So, we're mindful of the need to be competitive in this evolving landscape.

Analyst
Waleed

Great. Thank you. And then maybe just a question on BMS-249. Do you have any idea of when we can see the -- the next data readout from that study?

Executive
Sean A. McCarthy

Unfortunately we don't at this stage. They are actively enrolling patients or have been. We can't speak to their timelines unfortunately or to impact that COVID may be having on their enrollment. So, we're just going to have to wait and see how that unfolds.

Analyst
Waleed

Great, thank you for taking the questions.

Executive
Sean A. McCarthy

You're welcome.

Operator
Operator

Thank you. Our next question comes from Etzer Darout of Guggenheim Securities. Your line is open.

Analyst
Etzer Darout

The first one for me is a little clarity on the CX-072 combination with CX-2009, if that -- what you said was that you plan to sort of initiate a study there in the second half of this year. And then just a quick question on the Astellas Bispecific collaboration, obviously hematologic malignancies are where we've seen sort of the most success, but it's also kind of more crowded. I wondered, if you could talk about -- a little